Mengmeng Tang
Vice President Juncell Therapeutics
Mengmeng Tang is Vice President at Juncell Therapeutics, a clinical-stage biotech pioneering IL-2-independent tumor-infiltrating lymphocyte therapies for solid tumors. In her role, she is closely involved in advancing Juncell’s feeder-free, IL-2-free manufacturing platform. Her work that underpins the company’s approach to delivering a potential first-in-class TIL therapy. At the summit, she’ll share insights into how this manufacturing innovation is translating into clinical progress.
Seminars
Wednesday 18th November 2026
Advancing TIL Therapy in Advanced Melanoma With Clinical Evidence Supporting a Next Generation Treatment Approach
9:30 am
- Presenting pivotal clinical data from patients with advanced melanoma, demonstrating achievement of the study’s primary endpoint and supporting the potential for the first marketed TIL therapy in China
- Exploring innovations in treatment delivery through an IL-2-free regimen, low-intensity pretreatment, and a feeder-free manufacturing process designed to simplify therapy while maintaining clinical efficacy
- Examining outcomes in predominantly acral and mucosal melanoma populations and discussing what these findings could mean for the future evolution of TIL therapy
